Carmustine Replacement in Intensive Chemotherapy Preceding Reinjection of Autologous HSCs in Hodgkin and Non-Hodgkin Lymphoma: a Review

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2017 Jan 24

PMID 28112752

Citations 3

Authors

G Damaj

J Cornillon

K Bouabdallah

R Gressin

S Vigouroux

T Gastinne

F Ranchon

H Ghesquieres

G Salles

I Yakoub-Agha

E Gyan

Affiliations

Soon will be listed here.

Abstract

High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM. In addition to these two combinations, the present manuscript also summarizes data reported for other conditioning combinations. Owing to the lack of prospective and comparative studies, a comparison of the toxicities and medicoeconomical profiles of these treatments is warranted to identify effective replacements for BCNU-based conditioning.

Citing Articles

Prospective study on the impact of BEAM versus FEAM conditioning on occurrence of neutropenic enterocolitis and on transplant outcome in lymphoma patients.

Benedetti E, Traverso G, Pucci G, Morganti R, Bramanti E, Cavallo F Front Oncol. 2024; 14:1369601.

PMID: 38803538 PMC: 11128601. DOI: 10.3389/fonc.2024.1369601.

[Effect and safety of pegylated recombinant human G-CSF on hematopoietic reconstitution after autologous hematopoietic stem cell transplantation in lymphoma patients].

Shen Y, Ji M, Zheng Z, Tang W, Zhao W Zhonghua Xue Ye Xue Za Zhi. 2023; 43(11):940-945.

PMID: 36709186 PMC: 9808863. DOI: 10.3760/cma.j.issn.0253-2727.2022.11.010.

BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.

Ron-Magana A, Fernandez-Vargas O, Barrera-Chairez E, Ron-Guerrero C, Banuelos-Avila A Ann Transplant. 2019; 24:584-587.

PMID: 31636248 PMC: 6824191. DOI: 10.12659/AOT.918259.

References

Darwish M, Megason G, Bond M, Hellriegel E, Robertson Jr P, Grasela T . Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia. Curr Med Res Opin. 2014; 30(11):2305-15. DOI: 10.1185/03007995.2014.941976. View

Rummel M, Al-Batran S, Kim S, Welslau M, Hecker R, Kofahl-Krause D . Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23(15):3383-9. DOI: 10.1200/JCO.2005.08.100. View

DAmore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H . Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012; 30(25):3093-9. DOI: 10.1200/JCO.2011.40.2719. View

Visani G, Malerba L, Stefani P, Capria S, Galieni P, Gaudio F . BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011; 118(12):3419-25. DOI: 10.1182/blood-2011-04-351924. View

Tong W, LUDLUM D . Crosslinking of DNA by busulfan. Formation of diguanyl derivatives. Biochim Biophys Acta. 1980; 608(1):174-81. DOI: 10.1016/0005-2787(80)90145-8. View

Rancea M, Will A, Borchmann P, Monsef I, Engert A, Skoetz N . Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. J Natl Cancer Inst. 2014; 106(8). DOI: 10.1093/jnci/dju170. View

Dreyling M, Geisler C, Hermine O, Kluin-Nelemans H, Le Gouill S, Rule S . Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii83-92. DOI: 10.1093/annonc/mdu264. View

Phillips G, Shepherd J, Barnett M, Lansdorp P, Klingemann H, Spinelli J . Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol. 1991; 9(10):1880-8. DOI: 10.1200/JCO.1991.9.10.1880. View

Cheson B, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E . Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. Leuk Lymphoma. 2015; 57(4):766-82. PMC: 4840280. DOI: 10.3109/10428194.2015.1099647. View

10.

Gutierrez-Delgado F, Maloney D, Press O, Golden J, Holmberg L, Maziarz R . Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant. 2001; 28(5):455-61. DOI: 10.1038/sj.bmt.1703179. View

11.

Le Gouill S, de Guibert S, Planche L, Brice P, Dupuis J, Cartron G . Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011; 96(8):1128-35. PMC: 3148906. DOI: 10.3324/haematol.2010.030320. View

12.

Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N . Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010; 101(9):2059-64. PMC: 11159261. DOI: 10.1111/j.1349-7006.2010.01635.x. View

13.

Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P . High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012; 18(11):1677-86. PMC: 4010147. DOI: 10.1016/j.bbmt.2012.05.011. View

14.

Moskowitz A, Hamlin Jr P, Perales M, Gerecitano J, Horwitz S, Matasar M . Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2012; 31(4):456-60. PMC: 3862960. DOI: 10.1200/JCO.2012.45.3308. View

15.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G . High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006; 24(24):3865-70. DOI: 10.1200/JCO.2006.06.2117. View

16.

Cheson B, Wendtner C, Pieper A, Dreyling M, Friedberg J, Hoelzer D . Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010; 10(1):21-7. DOI: 10.3816/CLML.2010.n.002. View

17.

Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquieres H . Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica. 2012; 97(11):1751-6. PMC: 3487451. DOI: 10.3324/haematol.2011.060434. View

18.

Oh D, Chua N, Street L, Stewart D . Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leuk Lymphoma. 2015; 57(1):28-33. DOI: 10.3109/10428194.2015.1026901. View

19.

Bergmann M, Goebeler M, Herold M, Emmerich B, Wilhelm M, Ruelfs C . Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005; 90(10):1357-64. View

20.

Sellner L, Boumendil A, Finel H, Choquet S, De Rosa G, Falzetti F . Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant. 2015; 51(2):212-218. DOI: 10.1038/bmt.2015.273. View